Cancer's genetic basis underpins the burgeoning field of personalized medicine.  Advances in genomics, particularly next-generation sequencing, have revolutionized our understanding of oncogenesis, revealing the complex interplay of driver mutations, tumour suppressor gene inactivation, and epigenetic modifications unique to each patient's cancer. This knowledge allows for targeted therapies, a cornerstone of personalized oncology.  

The interdisciplinary nature of this field is crucial.  Bioinformaticians analyze vast genomic datasets, identifying crucial mutations and predicting therapeutic response.  Molecular biologists delve into the pathways affected by these mutations, informing drug development.  Clinicians translate these findings into individualized treatment plans, while bioethicists grapple with the ethical implications of genetic testing and targeted therapies.  This collaborative effort, integrating expertise from diverse disciplines, is essential for maximizing the benefits of personalized cancer treatment, moving beyond the 'one-size-fits-all' approach to a more precise and effective strategy.